We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 169

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients


President Trump Nominates Scott Mugno of FedEx to Head OSHA: Things to Watch For
  • Ogletree Deakins
  • USA
  • November 2 2017

On Monday, October 27, 2017, President Trump nominated Scott Mugno, currently the vice-president for safety at FedEx Ground, to be the new head of the


Council’s publicity campaign angers heritage lovers
  • Boodle Hatfield
  • United Kingdom
  • September 6 2017

A local English council has caused a furore once again over plans to promote itself internationally as a cultural heritage destination three years


Briefing Underway in Appeal of Half-Billion-Dollar Verdict in Pinnacle MDL
  • Cozen O'Connor
  • USA
  • March 9 2017

We've been following the Pinnacle MDL closely through the last two bellwether trials, starting with the news coming out of the second bellwether


Biosimilar FDA Approvals on the Horizon As More States Enact Substitution Laws
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • August 30 2016

In a sign of growing scientific acceptance and understanding of the biosimilar regulatory pathway, FDA's Arthritis Advisory Committee (AAC) voted


A Tour of NAD Takes on Claims
  • Kelley Drye & Warren LLP
  • USA
  • August 15 2016

The NAD recently reviewed claims for an omega-3 supplement. See Prevention Pharmaceuticals, Inc., NAD Case No. 5966 (July 2016). The NAD found that


Secondary Considerations Change Panel’s Mind after Institution
  • Marshall Gerstein & Borun LLP
  • USA
  • August 11 2016

The PTAB is not often persuaded by objective evidence of non-obviousness, i.e., secondary considerations, when the scope and content of the prior art


I’m not racist, butSection 18C of the Racial Discrimination Act - not an argument worth having
  • MARQUE Lawyers
  • Australia
  • August 11 2016

We need to talk about section 18C of the Racial Discrimination Act. What it does and doesn't do. There seems to be some confusion (we're looking at


Watch: Biotech Investment Opportunities - What You Need to Know
  • Dechert LLP
  • USA
  • July 27 2016

Biotechnology companies have faced turmoil in the public markets in the first several months of the year amid concerns about pricing, and growing


At the Federal Circuit - Applying the Doctrine of Equivalents: Both Intrinsic and Extrinsic Evidence Can Be Relied Upon in Determining the Function of a Claimed Element
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • June 30 2016

The Federal Circuit in Intendis GmbH v. Glenmark Pharmaceuticals Inc., USA, No. 2015-1902 (Fed. Cir. May 16, 2016) affirmed the district court's